Vorinostat

Back to search

Molecule Structure

Scientific Name

Vorinostat

Description of the Drug

Vorinostat is a histone deacetylase (HDAC) inhibitor used for the treatment of cutaneous manifestations in patients with progressive, persistent, or recurrent cutaneous T- cell lymphoma (CTCL) following prior systemic therapies.

Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB02546

Brand Name(s)

Zolinza

Company Owner(s)

Merck Sharp And Dohme Llc A Sub Of Merck And Co Inc

Mechanism(s) Of Action

Target Name Target Type Action Type Target ChEMBL ID
Histone deacetylase 6 SINGLE PROTEIN INHIBITOR CHEMBL1865
Histone deacetylase 1 SINGLE PROTEIN INHIBITOR CHEMBL325
Histone deacetylase 3 SINGLE PROTEIN INHIBITOR CHEMBL1829
Histone deacetylase 2 SINGLE PROTEIN INHIBITOR CHEMBL1937

Unichem Links

Atlas SAHA vorinostat
SureChEMBL SCHEMBL9018
PharmGKB PA164748224
Human Metabolome Database HMDB0015568
DrugBank DB02546
PubChem: Thomson Pharma 14823867
PubChem 5311
Mcule MCULE-4234367506
NMRShiftDB 80021416
LINCS LSM-3828
Nikkaji J653.349C
PDBe SHH
BindingDB 19149
EPA CompTox Dashboard DTXSID6041133
DrugCentral 4124
Brenda 7817 1547 217024 41261 237067 206568 151869
ChemicalBook CB3506806
Guide to Pharmacology 6852
rxnorm VORINOSTAT ZOLINZA
PubChem: Drugs of the Future 12015019
ChEBI 45716
ZINC ZINC000001543873